vTv Therapeutics Inc (VTVT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, vTv Therapeutics Inc (VTVT) has a cash flow conversion efficiency ratio of -0.029x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.29 Million) by net assets ($78.63 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see vTv Therapeutics Inc (VTVT) market capitalisation for the company's overall valuation and market capitalisation.
vTv Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how vTv Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
vTv Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of vTv Therapeutics Inc ranked by their cash flow conversion efficiency. Explore VTVT operating cash flow to net income to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Creades AB Series A
LSE:0QI9
|
-0.001x |
|
Zapata Computing Holdings Inc. Common Stock
NASDAQ:ZPTA
|
0.032x |
|
UJU Electronics Co. Ltd
KQ:065680
|
0.010x |
|
Mr. Blue Corporation
KQ:207760
|
-0.006x |
|
Chun Yu Works & Co Ltd
TW:2012
|
0.007x |
|
Stomil Sanok SA
WAR:SNK
|
0.014x |
|
Valiant Organics Limited
NSE:VALIANTORG
|
0.121x |
|
Sejong Industrial
KO:033530
|
0.053x |
Annual Cash Flow Conversion Efficiency for vTv Therapeutics Inc (2013–2025)
The table below shows the annual cash flow conversion efficiency of vTv Therapeutics Inc from 2013 to 2025. View VTVT live share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $64.44 Million | $-25.25 Million | -0.392x | +77.85% |
| 2024-12-31 | $14.30 Million | $-25.31 Million | -1.770x | -272.03% |
| 2023-12-31 | $-18.55 Million | $-19.08 Million | 1.029x | +139.40% |
| 2022-12-31 | $5.84 Million | $-15.25 Million | -2.611x | -105.85% |
| 2021-12-31 | $15.22 Million | $-19.31 Million | -1.268x | +73.27% |
| 2020-12-31 | $3.79 Million | $-18.00 Million | -4.746x | -282.25% |
| 2019-12-31 | $-8.84 Million | $-23.02 Million | 2.604x | +703.31% |
| 2018-12-31 | $-82.85 Million | $-26.86 Million | 0.324x | +9.88% |
| 2017-12-31 | $-151.05 Million | $-44.56 Million | 0.295x | -44.35% |
| 2016-12-31 | $-90.94 Million | $-48.21 Million | 0.530x | +11.87% |
| 2015-12-31 | $-77.97 Million | $-36.95 Million | 0.474x | +667.92% |
| 2014-12-31 | $-498.81 Million | $-30.78 Million | 0.062x | -55.04% |
| 2013-12-31 | $-303.73 Million | $-41.68 Million | 0.137x | -- |
About vTv Therapeutics Inc
vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. The company… Read more